If you missed the live session, you can now watch the full webinar on demand.

What you’ll learn:

• How lentiviral vector production differs between adherent and suspension-based systems, and what this means for process development.
• How HEK293T cells can be adapted to suspension culture and characterised for scalable LV production.
• How to assess cell line suitability when developing a process that may later move toward GMP manufacturing.
• How transfection conditions can influence vector yield, consistency and process performance.
• How stirred-tank reactor scale-up can be approached using practical engineering parameters.
• How to design a scale-up pathway that supports reproducibility across different bioreactor platforms.
• How to prepare a suspension-based LV production process for transfer into a GMP environment.

In this webinar, Lindsay Mulder, Scientist Viral Vector at NecstGen, presents a practical case study on upstream development of a suspension-based lentiviral vector production platform using HEK293T cells.

The session builds on the concepts introduced in Lodewijk’s previous webinar and gives you a step-by-step view of how the process was established, optimised and scaled.

This replay is relevant for viral vector process development scientists, engineers and manufacturing teams who want to better understand how systematic development strategies can support scalable LV production and strengthen the technical foundation for GMP transfer.

If you have additional questions, we invite you to share them with the NecstGen team.